Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Identifying Patients in Whom the Follow-up Scheme after Robot-assisted Radical Prostatectomy Could be Optimized in the First Year after Surgery: Reducing Healthcare Burden

Hans Veerman
* ORCID logo ,
Sophia Van der Graaf
ORCID logo ,
Dennie Meijer
ORCID logo ,
Marinus Jan Hagens
,
Corinne N. Tillier
,
Pim J. Van Leeuwen
,
Henk G. Van der Poel
,
André N. Vis
Version 1 : Received: 14 January 2023 / Approved: 16 January 2023 / Online: 16 January 2023 (07:38:27 CET)

A peer-reviewed article of this Preprint also exists.

Veerman, H.; van der Graaf, S.H.; Meijer, D.; Hagens, M.J.; Tillier, C.N.; van Leeuwen, P.J.; van der Poel, H.G.; Vis, A.N. Identifying Patients in Whom the Follow-Up Scheme after Robot-Assisted Radical Prostatectomy Could Be Optimized in the First Year after Surgery: Reducing Healthcare Burden. Biomedicines 2023, 11, 727. Veerman, H.; van der Graaf, S.H.; Meijer, D.; Hagens, M.J.; Tillier, C.N.; van Leeuwen, P.J.; van der Poel, H.G.; Vis, A.N. Identifying Patients in Whom the Follow-Up Scheme after Robot-Assisted Radical Prostatectomy Could Be Optimized in the First Year after Surgery: Reducing Healthcare Burden. Biomedicines 2023, 11, 727.

Abstract

Background: The currently advised follow-up scheme of PSA-testing after robot-assisted radical prostatectomy (RARP) is strict and might pose a burden to our healthcare system. We aimed to optimize the 1-year follow-up scheme for patients who undergo RARP. Methods: All patients with histologically-proven prostate cancer (PCa) who underwent RARP between 2018 and August 2022 in the Prostate Cancer Network the Netherlands were retrospectively evaluated. We excluded patients who underwent salvage RARP and patients who had <1 year of PSA follow-up. Postoperative PSA-values were collected. Biochemical persistence (BCP) was defined as PSA-level >0.10 ng/mL at 0-4 months after RARP, whereas biochemical recurrence (BCR) was defined as PSA-level >0.2 ng/mL at any time point after RARP. We aimed to identify a group of patients who had a very low risk of BCR at different time-points after surgery. Results: Of all 1155 patients, BCP was observed in 151 (13%), of whom 79 (6.8%) had PSA ≥0.2 ng/mL. BCR further developed in 51 (4.7%), and 37 (3.4%) patients at 5-8 and 9-12 months after RARP, respectively. In 12 patients, BCR was found at 5-8 months after RARP in absence of BCP. These patients represented 1.2% (12/1004) of the entire group. In other words, 98.8% (992/1004) of patients who had an unmeasurable PSA-level at 0-4 months after RARP also had unmeasurable PSA-level 5-8 months after surgery. Limitations are the retrospective design and incomplete follow-up. Conclusions: Patients with an unmeasurable PSA-level at 3-4 months after RARP may not need to be retested until 12 months of follow-up as almost 100% of patients will not have biochemically recurrent disease at 5-8 months of follow-up. This will reduce PSA-testing substantially at the costs of hardly any missed patients with recurrent disease.

Keywords

prostatic neoplasms; prostatectomy; prostate-specific antigen; follow-up; aftercare; recurrence; delivery of healthcare

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.